• Optimizing Protein Stability for Dual OXPHOS Targeting in Ca

  2026-06-11

  This thought-leadership article explores the mechanistic and translational imperatives for precise protease inhibition in advanced cancer research, spotlighting the synergy between LRPPRC inhibition and Dasatinib in dual-genome OXPHOS disruption. It highlights the critical role of EDTA-free protease inhibitor cocktails—specifically APExBIO's DMSO-formulated solution—in ensuring data fidelity during complex protein extraction workflows. The article bridges experimental evidence, protocol optimization, and strategic guidance for translational researchers, while contextualizing its contribution within and beyond existing literature.

• Cy3 TSA Fluorescence System Kit for Quantitative Lipogenesis

  2026-06-11

  Explore how the Cy3 TSA Fluorescence System Kit enables ultra-sensitive, quantitative mapping of de novo lipogenesis pathways in cancer research. This in-depth analysis bridges advanced signal amplification with transcriptional regulation insights, providing new protocols and practical guidance.

• 25-Hydroxycholesterol Drives Lysosomal AMPK Activation in TA

  2026-06-10

  Xiao et al. (2024) elucidate how lysosomal 25-hydroxycholesterol (25HC) activates AMPKα via the GPR155-mTORC1 complex in tumor-associated macrophages (TAMs), promoting STAT6-dependent immunosuppressive programming. Targeting the CH25H-25HC-AMPK axis reprograms macrophage metabolism and enhances antitumor immunity, revealing new intervention points for improving immunotherapy.

• 2-Deoxy-D-glucose: Applied Glycolysis Inhibition in Cancer R

  2026-06-10

  2-Deoxy-D-glucose (2-DG) from APExBIO enables precise metabolic modulation in cancer, immunology, and virology workflows. This guide details advanced use-cases, stepwise experimental protocols, and troubleshooting strategies for maximizing 2-DG's impact as a glycolysis inhibitor and metabolic oxidative stress inducer.

• Sorafenib (BAY-43-9006) in Cancer Biology: Applied Workflows

  2026-06-09

  Sorafenib (BAY-43-9006) stands out as a robust cancer biology research tool, enabling precise dissection of antiangiogenic and antiproliferative mechanisms in tumor models. This article delivers workflow-level guidance, protocol optimization, and troubleshooting strategies to maximize the impact of Sorafenib in both in vitro and in vivo experimental designs.

• 2-Deoxy-D-glucose: Optimizing Glycolysis Inhibition in Resea

  2026-06-09

  2-Deoxy-D-glucose (2-DG) enables precise modulation of cellular metabolism, unlocking advanced workflows in cancer, immunometabolic, and antiviral research. This article translates recent protocol innovations and troubleshooting strategies into actionable steps for reproducible, high-impact assays.

• Meropenem Trihydrate: Carbapenem Antibiotic Workflows & Insi

  2026-06-08

  Meropenem trihydrate stands as a powerful carbapenem antibiotic for dissecting resistance mechanisms and modeling infections in translational research. This article provides actionable protocols, troubleshooting strategies, and metabolomics-driven insights—empowering researchers with reproducible, data-driven workflows using APExBIO's trusted reagent.

• Advancing Translational Immunotherapy with 2X HyperFusion™ P

  2026-06-08

  Discover how APExBIO's 2X HyperFusion™ High-Fidelity Master Mix is redefining the foundation of translational immunotherapy research. This deep-dive examines the mechanistic rationale, experimental needs, and strategic guidance for employing high-accuracy, blunt-end PCR in next-generation CRISPR and cancer immunotherapy workflows—leveraging insights from recent bufalin-CRISPR/Cas9 nanomedicine breakthroughs in colorectal cancer.

• Tofacitinib Citrate (CP-690550): Precision Tools for JAK3-Dr

  2026-06-07

  Explore the unique immunological precision of Tofacitinib citrate (CP-690550 citrate) in dissecting JAK-STAT signaling and lymphocyte modulation. This article delivers a fresh, in-depth analysis of how JAK3-selective inhibition informs immune regulation and inflammatory disorder research, grounded in the latest endothelial cell and cardiovascular findings.

• (S)-Mephenytoin: Gold-Standard CYP2C19 Substrate for In Vitr

  2026-06-06

  (S)-Mephenytoin is a validated CYP2C19 substrate widely applied in oxidative drug metabolism and pharmacokinetic studies. Its well-defined enzyme kinetics, high specificity, and compatibility with human-relevant in vitro models make it the preferred choice for benchmarking CYP2C19 function in research assays.

• Olaparib (AZD2281, Ku-0059436): Best Practices for Reliable

  2026-06-05

  This article provides scenario-driven, evidence-based guidance for using Olaparib (AZD2281, Ku-0059436), SKU A4154, in DNA damage response and tumor radiosensitization studies. Designed for biomedical researchers and laboratory scientists, it addresses real workflow challenges and offers practical, data-backed solutions for reproducible cancer research.

• Lyso-Tracker Red DND-99: Optimizing Lysosome Labeling in Liv

  2026-06-05

  Lyso-Tracker Red DND-99 stands out for its high specificity and reliability in lysosome labeling within live cells, enabling researchers to dissect lysosomal dynamics with precision. This article guides users through practical protocols, advanced applications, and troubleshooting tips, bridging recent nanozyme and immunotherapy research with actionable experimental workflows.

• SIX1 Drives De Novo Lipogenesis in Liver Cancer via DGUOK-AS

  2026-06-04

  This study uncovers how the transcription factor SIX1 promotes de novo lipogenesis (DNL) in liver cancer cells by directly upregulating key metabolic enzymes through cooperation with histone acetyltransferases. The research further elucidates a regulatory axis involving DGUOK-AS1 and microRNA-145-5p, providing new mechanistic insight into lipid metabolism’s role in liver cancer progression and potential targets for intervention.

• TEAD2 Upregulation in HCC: Prognostic Marker and Ferroptosis

  2026-06-04

  This study integrates bioinformatics and experimental analysis to identify TEAD2 as a novel prognostic marker in hepatocellular carcinoma (HCC) and clarify its role in regulating ferroptosis. The findings provide actionable insights for targeting TEAD2 and ferroptosis pathways in HCC research and therapeutic development.

• Fzd5 Cholesterol Sensing Links Lipid Metabolism to Wnt Signa

  2026-06-03

  This study uncovers a unique mechanism by which Frizzled5 (Fzd5) specifically senses cholesterol, facilitating Wnt/β-catenin signaling and supporting pancreatic cancer growth. The findings bridge lipid metabolic regulation with morphogen pathways, offering new insight into cancer biology and therapeutic potential.

15605 records 1/1041 page Next 12345 下5页 Last page